Search
Research
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papilloma VirusWe conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys...
Research
Predominance of nontypeable haemophilus influenzae in children with otitis mediaIn Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Research
Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell toleranceConcerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...
Research
Slam and dc-sign measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccineDespite the use of measles vaccine, measles virus continues to circulate and cause severe disease
News & Events
Free vaccines for pregnant mums see monumental rise in protection for WA babiesNew collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.
News & Events
RSV prevention finally in reach after 20 years of research at The Kids Research Institute AustraliaWorld-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.
Research
ATAGI Targeted Review 2021: the national COVID-19 vaccination programThe overarching goal of the Australian coronavirus disease 2019 (COVID-19) vaccination program has been to protect all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2. This review reflects on the role of the Australian Technical Advisory Group on Immunisation (ATAGI) in the national COVID-19 vaccination program, in terms of the initial programmatic and clinical recommendations in the evolving context of evidence relating to the disease and vaccines, epidemiology, and the program rollout.